We conducted a nationwide retrospective cohort study to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection among recipients of 4 different vaccines in South Korea. Age-adjusted breakthrough infection rate per month was highest for Janssen (42.6/100,000 population), followed by AstraZeneca (21.7/100,000 population), Pfizer-BioNTech (8.5/100,000 population), and Moderna (1.8/100,000 population).
All Keywords
【저자키워드】 COVID-19, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, Vaccine, coronavirus, breakthrough, South Korea, 【초록키워드】 Breakthrough infection, Pfizer-BioNTech, AstraZeneca, Moderna, janssen, retrospective cohort study, acute respiratory syndrome, recipient, highest, conducted,
【저자키워드】 COVID-19, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, Vaccine, coronavirus, breakthrough, South Korea, 【초록키워드】 Breakthrough infection, Pfizer-BioNTech, AstraZeneca, Moderna, janssen, retrospective cohort study, acute respiratory syndrome, recipient, highest, conducted,